What myalgic encephalomyelitis / chronic fatigue syndrome is
Myalgic encephalomyelitis, also called chronic fatigue syndrome (ME/CFS), is a complex, long-term neurological condition. Its defining feature is post-exertional malaise: a worsening of symptoms following physical, cognitive, or emotional effort that would previously have been tolerable, with recovery taking days or longer. Other core symptoms include profound fatigue not relieved by rest, unrefreshing sleep, cognitive difficulties (sometimes called brain fog), and orthostatic intolerance. Pain — muscular, joint, and headache — is common. The cause is not fully understood; immunological, metabolic, autonomic nervous system, and mitochondrial abnormalities have all been documented. There is no single diagnostic test and no cure. Estimated prevalence in the UK is around 250,000 people, though underdiagnosis is widespread.
Cannabis research on Myalgic encephalomyelitis / chronic fatigue syndrome
Very few studies have directly examined cannabis or cannabinoids for ME/CFS. No randomised controlled trial of cannabis for ME/CFS was found in the cited literature. What exists is indirect evidence from related conditions and a small number of observational reports.
A 2014 review by Smith and Wagner revisited the clinical endocannabinoid deficiency (CECD) hypothesis first proposed by Ethan Russo. The CECD concept suggests that some functional disorders characterised by hypersensitivity to pain and other stimuli — specifically migraine, fibromyalgia, and irritable bowel syndrome — may involve insufficient endocannabinoid system tone. The review noted that cannabinoids can block spinal, peripheral, and gastrointestinal mechanisms that promote pain in these conditions. ME/CFS was not a primary focus of the CECD hypothesis, but the symptom overlap with fibromyalgia (pain, sleep disturbance, fatigue, cognitive dysfunction) means the concept is relevant to the broader question of whether endocannabinoid function is altered in ME/CFS. No studies have directly measured endocannabinoid levels in people with ME/CFS.
The nearest clinical evidence comes from fibromyalgia studies. A 2023 systematic review by Khurshid and colleagues analysed 22 articles on cannabinoids for fibromyalgia and described medical cannabis as safe and used for fibromyalgia pain, but the review noted gaps in dosage information, long-term effect data, and dependence risk. The evidence quality was rated low. A separate 2016 systematic review by Fitzcharles and colleagues of RCTs for rheumatic pain — including two nabilone trials in 71 fibromyalgia patients — found that superiority of cannabinoids over controls was not consistent, and concluded that there was insufficient evidence to recommend any cannabinoid preparation for symptom management in rheumatic disease-related chronic pain.
A 2023 retrospective medical record review by Morris and colleagues of 157 Australian adults prescribed medicinal cannabis for non-cancer diagnoses found significant improvements in multiple symptom domains including fatigue, sleep, pain, and mood (all p < 0.0001). The greatest perceived effect was on sleep (80.0%), followed by pain (51.5%). The population was predominantly neurological and musculoskeletal patients with a mean age of 63 years; ME/CFS was not a specific diagnostic subgroup.
On the biological side, the endocannabinoid system is involved in pain processing, sleep regulation, immune function, and energy metabolism — all systems implicated in ME/CFS. CB1 and CB2 receptors are widely distributed in the central nervous system and on immune cells. Animal research has shown that cannabinoids can modulate neuroinflammation and microglial activation. These are preclinical and mechanistic observations. They do not establish that cannabis or cannabinoids improve ME/CFS symptoms in people.
Patient-led surveys and online communities report substantial use of cannabis for ME/CFS self-management, particularly for pain, sleep, and nausea. These reports are uncontrolled and subject to self-selection bias: people who find cannabis unhelpful are less likely to participate in cannabis-focused surveys or report their experience. No peer-reviewed survey specifically of ME/CFS patients’ cannabis use has been identified in the cited literature.
Compounds studied for Myalgic encephalomyelitis / chronic fatigue syndrome
THC acts on CB1 receptors in the central nervous system and has been studied in human clinical trials for chronic pain, including in fibromyalgia. The fibromyalgia evidence is relevant because of symptom overlap with ME/CFS, but the two conditions are distinct and findings do not transfer directly. THC’s known side effects include somnolence and cognitive impairment, which are relevant given existing fatigue and brain fog in ME/CFS.
CBD has been studied in preclinical models for neuroinflammation and microglial modulation. In animal studies, CBD has shown anti-inflammatory effects in the central nervous system. No human trial has tested CBD for ME/CFS. In the fibromyalgia literature, CBD has been studied both alone and in combination with THC, with mixed results at low evidence quality.
CBG has been studied in preclinical research for its interaction with alpha-2 adrenergic receptors, which are involved in sympathetic nervous system function. Orthostatic intolerance and autonomic dysfunction are common in ME/CFS, making this a biologically notable pathway, but this is entirely at the laboratory stage and no human data exists.
Beta-caryophyllene is a CB2 receptor agonist with anti-inflammatory properties in preclinical models. Given the evidence of neuroinflammation and immune dysfunction in ME/CFS, CB2 agonism is a biologically plausible pathway. This is laboratory research and does not establish a therapeutic effect in ME/CFS.
Pinene has been studied in preclinical models for its acetylcholinesterase-inhibiting properties, which could theoretically affect cognitive function. Brain fog is a core ME/CFS symptom. This is speculative and based on preclinical pharmacology, not human trial data.
Myrcene has shown analgesic and sedative effects in animal studies. Pain and unrefreshing sleep are common in ME/CFS. These are preclinical findings, not specific to ME/CFS.
Limits of the evidence for Myalgic encephalomyelitis / chronic fatigue syndrome
No randomised controlled trial of cannabis for ME/CFS was found in the cited literature. No clinical trial of any cannabinoid specifically for ME/CFS was identified. The direct evidence base for this condition is essentially absent.
The fibromyalgia evidence provides the nearest clinical comparison because of overlapping symptoms, but fibromyalgia and ME/CFS are separate diagnoses with different diagnostic criteria and, in some respects, different pathophysiology. Extrapolation from one to the other should be acknowledged as extrapolation, not equivalence.
The clinical endocannabinoid deficiency hypothesis is a conceptual framework, not a validated mechanism for ME/CFS. No study has measured endocannabinoid tone in people with ME/CFS or demonstrated that supplementing it with exogenous cannabinoids alters disease course.
Patient surveys and anecdotal reports indicate high interest and self-reported use, but these cannot substitute for controlled evidence. The gap between patient demand and clinical trial evidence in ME/CFS is one of the widest across any condition discussed on this site.
Cannabis side effects of particular concern in ME/CFS include sedation, cognitive slowing, and orthostatic dizziness — all of which overlap with existing ME/CFS symptoms and could compound functional impairment. These risks have not been systematically studied in this population.
Sources
1. Smith SC, Wagner MS. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2014;35(3):198-201. Study record 2. Khurshid H, et al. A systematic review of fibromyalgia and the role of the endocannabinoid system. Cureus. 2021;13(8):e17238. Study record 3. Fitzcharles MA, et al. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30(1):47-61. Study record 4. Morris M, et al. Medicinal cannabis in older adults with non-cancer diagnoses: a retrospective study. J Clin Med. 2023;12(7):2576. Study record 5. Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-165. Study record 6. Solmi M, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382:e072348. Study record
